PresentationGood day, and welcome to the Clipper Realty Q3 Earnings Call. [Operator Instructions] It is now my pleasure to turn the floor over to your host, Lawrence Sava. Sir, the floor is yours.Lawrence Sava Good afternoon, and thank you for joining us for the Third Quarter 2025 Clipper Realty Inc. Earnings Conference Call. Participating with me on today's call are David Bistricer, our Co-Chairman of the Board and Chief Executive Officer; J.J. Bistricer, Chief Operating Officer; and Larry Kreider, Chief F ...

Nov 13, 2025 6:14 PM Eastern Standard Time Superior Plus Declares 2025 Fourth Quarter Dividend Share TORONTO--(BUSINESS WIRE)--Superior Plus Corp. ("Superior†or "the company†) (TSX: SPB) announced today that its Board of Directors has approved a quarterly dividend of CAD $0.045 per common share payable on January 15, 2026, to shareholders of record at the close of business December 31, 2025. Superior's annualized cash dividend rate is currently CAD $0.18 per share. This dividend is an eligible dividend fo ...

TechPrecision (NasdaqCM:TPCS) Q2 2026 Earnings Call November 13, 2025 04:30 PM ET Speaker3Greetings and welcome to the TechPrecision Corporation FY 2026 Q2 financial results call. At this time, all participants are placed on a listen-only mode, and a question-and-answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note, this conference is being recorded. I will now turn the conference ...

NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Brookfield Asset Management Ltd. (“BAM”) (NYSE: BAM, TSX: BAM) a leading global alternative asset manager headquartered in New York with over $1 trillion of assets under management, today announced the pricing of a public offering of (i) $600 million principal amount of senior notes due 2030, which will bear interest at a rate of 4.653% per annum (the “2030 notes”), and (ii) $400 million principal amount of senior notes due 2036, which will bear interest at a rate ...

EARNINGS PRESENTATION THIRD QUARTER 2025 11.13.2025 DISCLOSURES FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Ac ...

RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that it intends to offer and sell its common shares in an underwritten registered public offering. In addition, Fennec intends to grant the underwriters a 30-day option to purchase up to an additional 15% of its common shares sold in the public offering. Fennec intends to use the net proceeds of the proposed offer ...

PORTLAND, Maine, Nov. 13, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended September 30, 2025. Product Sales Highlights: During the third quarter of 2025, product sales decreased by 8% to approximately $5.5 million ...

MALVERN, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights Revenue of $20.7 million, a 9% increase from the third quarter of 2024Revised full year 2025 revenue guidance of at least 16% growth over full year 2024 Recent Strategic Highlights Strengthened capi ...

PresentationI will now hand over to your host, Laura Nichols, Associate Director of Investor Relations, to begin. Please go ahead.Hello, and welcome, everyone, to the Aldeyra Therapeutics 2025 Research and Development Update Webcast. My name is Becky, and I'll be your operator today. [Operator Instructions].Laura NicholsOperations Manager Thank you, and good morning, everyone. Today, we issued a press release announcing the expansion of Aldeyra's RASP platform into central nervous system diseases and provid ...

公司交易动态 - Inventiva公司宣布其普通股于2025年11月13日下午4:30（CET）在巴黎泛欧交易所受监管市场恢复交易 [1] - 公司普通股交易于2025年11月13日上午9:00（CET）应公司要求暂停 以便确认美国存托凭证发行的投资者分配并公布发行定价 [2] 公司业务与产品管线 - 公司为临床阶段生物制药公司 专注于研发口服小分子疗法以治疗MASH患者 [3] - 公司核心产品lanifibranor是一种新型泛PPAR激动剂 目前正处于针对MASH成人患者的NATiV3关键性III期临床试验阶段 [3] 公司上市信息 - 公司在巴黎泛欧交易所受监管市场B区上市（代码：IVA） 同时在美国纳斯达克全球市场上市（代码：IVA） [4]